Boston Scientific Beats Estimates, Faces Challenges

Boston Scientifics Q1 2026 results exceeded expectations with a 11.6% revenue increase to $5.2 billion, driven by strong demand in neuromodulation and interventional cardiology. Adjusted EPS beat forecasts by 1.6%, and operating margins improved to 21.5%. Shares surged 9.2% to $64.79. However, challenges in urology and standalone WATCHMAN procedures due to sales team turnover and competition from Medtronic and Abbott led to revised Q2 revenue guidance and full-year adjusted EPS. Management plans to counter with new hires, cost controls, and launches like next-gen FARAPULSE. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3f87d0d2b6d04f37